Venus Remedies outlicenses Elores to Korean major Goodwills Co after Patent grant

02 May 2013 Evaluate

Venus Remedies has outlicensed Elores to a South Korean market leader after its patent grant from Companies and Intellectual Property Registration Office (CIPRO) from Republic of South Korea. The dossier for this product is already under evaluation by KFDA. Venus and Korean major Goodwills Co were in talks and negotiations for this deal from a long time. South Korean major is expecting to launch this product in 2014 after approval from Korean FDA. A bridging clinical trial has already been initiated on Korean population and which is currently running across 6 leading hospitals of Seoul, the capital city of South Korea.

Goodwills Co will have exclusive marketing rights of the product in South Korea till patent validity in 2025. ELORES is expected to be launched by mid of 2014 after getting due regulatory approvals from KFDA making it second deal of its kind in a year. Further, grant of the Patent is another testimony to the merits and uniqueness of Elores.

Elores is an antibiotic product meant for multi-drug resistant infections in ICU, specially in hospital acquired infection where the rise in resistance reported to the extent of >70% in Asia Pacific region. ELORES is a novel antibiotic adjuvant entity (AAE) to combat antimicrobial resistance caused by ESBL producing strains, product is effective against Metallo betalactamases (MBL) producing pathogens which are not susceptible to most of the existing antibiotics.

Venus Remedies Share Price

825.80 39.30 (5.00%)
11-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.90
Dr. Reddys Lab 1272.95
Cipla 1512.10
Zydus Lifesciences 922.45
Lupin 2080.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×